| DB ID | MyCo_5929 |
| Title | Aspergillus fumigatus enhances human NK cell activity by regulating M1 macrophage polarization |
| Year | 2019 |
| PMID | 31173233 |
| Fungal Diseases involved | Fungal infection |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | The present study was approved by the Ethics Committee of Changchun Blood Center, Jilin, China and conducted in accordance with the approved guidelines for the ‘Use of haemocytes in research’. Written informed consent for the use of haemocytes in research was obtained from all participants. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Biopsy |
| Sample source | Extracted RNA |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | TNFα |
| Biomarker Full Name | Tumour necrosis factor alpha |
| Biomarker Type | Diagnostic |
| Biomolecule | Gene |
| Geographical Location | China |
| Cohort | The A. fumigatus strain was obtained from the Medical Mycology Research Center of Chiba University. A. fumigates resting conidia were cultivated for 3 days on beer mash plates at 28˚C. Peripheral blood mononuclear cells (PBMCs) were freshly isolated from the peripheral blood of 3 healthy individuals at the Changchun Blood Center between May 2017 and September 2017. The 3 donors were all male (24‑32 years old). The donors were all negative for hepatitis B, hepatitis C and human immunodeficiency virus infection. PBMCs were isolated via Ficoll density gradient separation at 500 x g for 30 min at room temperature. |
| Cohort No. | 3 |
| Age Group | 24-32 |
| P Value | p<0.01 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Aspergillus fumigatus (A. fumigatus) is an environmentally ubiquitous, spore‑forming mould saprophyte that causes disease in individuals with poor immunity. The incidence of invasive fungal infections is increased in patients receiving bone marrow and organ transplantation, chemotherapy for cancer, or treatment with glucocorticoids or broad-spectrum use of antibiotics. Aspergillosis is the second most common type of fungal infection following candidiasis. The use of antifungal agents improves the prognosis of patients to a certain extent; however, the mortality rate of invasive Aspergillosis remains high due to the limited efficacy of currently available drugs. Infection-mediated immune injury is an important cause of death. Immunological diagnosis, prevention and reconstitution are crucial to improving the prognosis of patient recovery. Improved understanding of the regulatory mechanisms underlying the host immune response following invasive aspergillosis may aid in improving the prognosis of patients. |
| Technique | PCR |
| Analysis Method | RT‑qPCR |
| ELISA kits | ELISA Kit TNF‑α (cat. no. BMS223‑4; Invitrogen; Thermo Fisher Scientific, Inc.), IL‑ 18 (cat. no. BMS267‑2; Invitrogen; Thermo Fisher Scientific, Inc.), Galectin‑9 (cat. no. DGAL 90; R&D Systems, Inc.), IL‑ 12 (cat. no. BMS238; Invitrogen; Thermo Fisher Scientific, Inc.) and IL‑ 10 (cat. no. BMS215‑2; Invitrogen; Thermo Fisher Scientific, Inc.). |
| Assay Data | None |
| Validation Techniques used | ELISA, qRT-PCR, Flow Cytometry |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
